Development and validation of a nomogram for steroid-resistance prediction in immune thrombocytopenia patients

References

• Barsam SJ, Psaila B, Forestier M, et al. Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. Blood. 2011 May;117(21):5723–5732.
   PubMed Web of Science ®Google Scholar
• Audia S, Mahevas M, Samson M, et al. Pathogenesis of immune thrombocytopenia. Autoimmun Rev. 2017 Jun;16(6):620–632.
   PubMed Web of Science ®Google Scholar
• Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017 May;129(21):2829–2835.
   PubMed Web of Science ®Google Scholar
• Piel-Julian ML, Mahevas M, Germain J, et al. Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults. J Thromb Haemostasis. 2018 Sep;16(9):1830–1842.
   PubMed Web of Science ®Google Scholar
• Cooper N, Ghanima W. Immune thrombocytopenia. N Engl J Med. 2019 Sep;381(10):945–955.
   PubMed Web of Science ®Google Scholar
• Brown TM, Horblyuk RV, Grotzinger KM, et al. Patient-reported treatment burden of chronic immune thrombocytopenia therapies. BMC Blood Disord. 2012 Mar 22;12:2.
   PubMedGoogle Scholar
• Kao JH. Diagnosis of hepatitis B virus infection through serological and virological markers. Expert Rev Gastroenterol Hepatol. 2008 Aug;2(4):553–562.
   PubMedGoogle Scholar
• Sharma SK, Saini N, Chwla Y. Hepatitis B virus: inactive carriers. Virol J. 2005 Sep 28;2:82. DOI:https://doi.org/10.1186/1743-422X-2-82.
   PubMed Web of Science ®Google Scholar
• Gerlich WH. Medical virology of hepatitis B: how it began and where we are now. Virol J. 2013 Jul 20;10:239.
   PubMed Web of Science ®Google Scholar
• Adams PC, Barton JC. A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation. J Hepatol. 2011 Aug;55(2):453–458.
   PubMed Web of Science ®Google Scholar
• Efstathiou SP, Pefanis AV, Tsiakou AG, et al. Fever of unknown origin: discrimination between infectious and non-infectious causes. Eur J Intern Med. 2010 Apr;21(2):137–143.
   PubMed Web of Science ®Google Scholar
• Ihlow J, Gross S, Sick A, et al. AML: high serum ferritin at initial diagnosis has a negative impact on long-term survival. Leuk Lymphoma. 2019 Jan;60(1):69–77.
   PubMed Web of Science ®Google Scholar
• Chen XQ, Long XF, Liang ZG, et al. Higher N stage and serum ferritin, but lower serum albumin levels are associated with distant metastasis and poor survival in patients with nasopharyngeal carcinoma following intensity-modulated radiotherapy. Oncotarget. 2017 Sep;8(42):73177–73186.
   PubMedGoogle Scholar
• Ferreira KPZ, Oliveira SR, Kallaur AP, et al. Disease progression and oxidative stress are associated with higher serum ferritin levels in patients with multiple sclerosis. J Neurol Sci. 2017 Feb;373:236–241.
   PubMed Web of Science ®Google Scholar
• Enomoto N, Oyama Y, Enomoto Y, et al. Prognostic evaluation of serum ferritin in acute exacerbation of idiopathic pulmonary fibrosis. Clin Respir J. 2018 Aug;12(8):2378–2389.
   PubMed Web of Science ®Google Scholar
• Taubert R, Hardtke-Wolenski M, Noyan F, et al. Hyperferritinemia and hypergammaglobulinemia predict the treatment response to standard therapy in autoimmune hepatitis. PLoS One. 2017 Jun;12(6):e0179074.
   Google Scholar
• Datz C, Felder TK, Niederseer D, et al. Iron homeostasis in the metabolic syndrome. Eur J Clin Invest. 2013 Feb;43(2):215–224.
   PubMed Web of Science ®Google Scholar
• Weismüller TJ, Kirchner GI, Scherer MN, et al. Serum ferritin concentration and transferrin saturation before liver transplantation predict decreased long-term recipient survival. Hepatology. 2011 Dec;54(6):2114–2124.
   PubMed Web of Science ®Google Scholar
• Walker NM, Stuart KA, Ryan RJ, et al. Serum ferritin concentration predicts mortality in patients awaiting liver transplantation. Hepatology. 2010 May;51(5):1683–1691.
   PubMed Web of Science ®Google Scholar
• Okamoto O, Oishi M, Fujiwara S. Steroid-resistant adult-onset still's disease which showed a quick response to methotrexate. J Dermatol. 2008 Feb;35(2):106–110.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Cipriani P, Di Benedetto P, et al. H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome. Clin Exp Immunol. 2018 Feb;191(2):220–228.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Tsuboi H, Kurata I, et al. Predictors of the response to treatment in acute lupus hemophagocytic syndrome. Lupus. 2015 Jun;24(7):659–668.
   PubMed Web of Science ®Google Scholar
• Di Buduo CA, Currao M, Pecci A, et al. Revealing eltrombopag's promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation. Haematologica. 2016 Dec;101(12):1479–1488.
   PubMed Web of Science ®Google Scholar
• Vlachodimitropoulou E, Chen YL, Garbowski M, et al. Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator. Blood. 2017 Oct;130(17):1923–1933.
   PubMed Web of Science ®Google Scholar
• Lambert MP, Witmer CM, Kwiatkowski JL. Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia. Am J Hematol. 2017 Jun;92(6):E88–E91.
   PubMed Web of Science ®Google Scholar
• Roth M, Will B, Simkin G, et al. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood. 2012 Jul;120(2):386–394.
   PubMed Web of Science ®Google Scholar
• Kalota A, Selak MA, Garcia-Cid LA, et al. Eltrombopag modulates reactive oxygen species and decreases acute myeloid leukemia cell survival. PLoS One. 2015 Apr;10(4):e0126691.
   Google Scholar
• Allegra A, Penna G, Alonci A, et al. Exacerbation of chronic idiopathic thrombocytopenic purpura following reactivation of an occult hepatitis B. Medical Oncology. 2010 Sep;27(3):912–914.
   PubMed Web of Science ®Google Scholar
• Cines DB, Bussel JB, Liebman HA, et al. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009 Jun;113(26):6511–6521.
   PubMed Web of Science ®Google Scholar
• Neunert C, Lim W, Crowther M, et al. The American society of hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011 Apr 21;117(16):4190–4207.
   PubMed Web of Science ®Google Scholar
• Kim EB, Kim DS, Park SJ, et al. Hepatitis B virus reactivation in a surface antigen-negative and antibody-positive patient after rituximab plus CHOP chemotherapy. Cancer Res Treat. 2008 Mar;40(1):36–38.
   PubMedGoogle Scholar
• Michalska Z, Stalke P, Witczak-Malinowska K, et al. Autoimmune reactions in HBV and HCV. Med Sci Monit. 2001 May;7(Suppl 1):175–180.
   PubMedGoogle Scholar
• Weksler BB. Review article: the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. Aliment Pharmacol Ther. 2007 Nov;26(Suppl 1):13–19.
   PubMed Web of Science ®Google Scholar
• Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol. 2009 Jan;46(1 Suppl 2):S2–14.
   PubMed Web of Science ®Google Scholar
• Lebano R, Rosato V, Masarone M, et al. The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report. BMC Res Notes. 2014 Jan 24;7:59.
   PubMedGoogle Scholar
• Hamaia S, Li C, Allain JP. The dynamics of hepatitis C virus binding to platelets and 2 mononuclear cell lines. Blood. 2001 Oct 15;98(8):2293–2300.
   PubMed Web of Science ®Google Scholar
• Chiao EY, Engels EA, Kramer JR, et al. Risk of immune thrombocytopenic purpura and autoimmune hemolytic anemia among 120 908 US veterans with hepatitis C virus infection. Arch Intern Med. 2009 Feb 23;169(4):357–363.
   PubMedGoogle Scholar
• Geier DA, Geier MR. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity. 2005 Jun;38(4):295–301.
   PubMed Web of Science ®Google Scholar
• Geier MR, Geier DA. A case-series of adverse events, positive re-challenge of symptoms, and events in identical twins following hepatitis B vaccination: analysis of the vaccine adverse event reporting system (VAERS) database and literature review. Clin Exp Rheumatol. 2004 Nov–Dec;22(6):749–755.
   PubMed Web of Science ®Google Scholar
• He Q, Song XY, Huang YC, et al. Dexamethasone stimulates hepatitis B virus (HBV) replication through autophagy. Med Sci Monit. 2018 Jul;24:4617–4624.
   PubMed Web of Science ®Google Scholar
• Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J. 2007 Oct;37(10):705–712.
   PubMed Web of Science ®Google Scholar
• Lindh M, Uhnoo I, Blackberg J, et al. Treatment of chronic hepatitis B infection: an update of Swedish recommendations. Scand J Infect Dis. 2008;40(6–7):436–450.
   PubMed Web of Science ®Google Scholar
• Maan R, Veldt BJ, Janssen HL. Eltrombopag for thrombocytopenic patients with chronic HCV infection. Gastroenterology. 2014 Jul;147(1):254–255..
   PubMed Web of Science ®Google Scholar
• Kayar Y, Danalioglu A, Kocaman O, et al. Eltrombopag: how secure in triple therapy of HCV? Acta Gastroenterol Belg. 2015 Dec;78(4):445–446.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Mahmud SN, Brigstocke SL, et al. Tapering eltrombopag in patients with chronic ITP: How successful is this and in whom does it work? Blood. 2015;126(23):1054.
   Web of Science ®Google Scholar
• Chang H, Tang TC, Hung YS, et al. Immune thrombocytopenia: effectiveness of frontline steroids and comparison of azathioprine, splenectomy, and rituximab as second-line treatment. Eur J Haematol. 2018 Oct;101(4):549–555.
   PubMed Web of Science ®Google Scholar
• Dou X, Yang R. Current and emerging treatments for immune thrombocytopenia. Expert Rev Hematol. 2019 Sep;12(9):723–732.
   PubMed Web of Science ®Google Scholar
• Mithoowani S, Arnold DM. First-line therapy for immune thrombocytopenia. Hamostaseologie. 2019 Aug;39(3):259–265.
   PubMed Web of Science ®Google Scholar
• Ahmed R, Devasia AJ, Viswabandya A, et al. Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children: splenectomy in ITP. Ann Hematol. 2016 Sep;95(9):1429–1434.
   PubMed Web of Science ®Google Scholar
• Kado R, McCune WJ. Treatment of primary and secondary immune thrombocytopenia. Curr Opin Rheumatol. 2019 May;31(3):213–222.
   PubMed Web of Science ®Google Scholar
• Lucchini E, Fanin R, Cooper N, et al. Management of immune thrombocytopenia in elderly patients. Eur J Intern Med. 2018 Dec;58:70–76.
   PubMed Web of Science ®Google Scholar
• González-López TJ, Sánchez-González B, Jarque I, et al. Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia. Eur J Haematol. 2020 Mar;104(3):259–270.
   PubMed Web of Science ®Google Scholar
• Uto Y, Fujiwara S, Arai N, et al. Age and bone marrow cellularity are associated with response to eltrombopag in Japanese adult immune thrombocytopenia patients: a retrospective single-center study. Rinsho Byori. 2015 May;63(5):548–556.
   PubMedGoogle Scholar